EP-1386 Stereotactic body radiation therapy for central early non small cell lung cancers-Yes! Its possible

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer.

INTRODUCTION Stereotactic body radiation therapy (SBRT) is being increasingly applied in the treatment of non-small cell lung cancer (NSCLC) because of its high local efficacy. This study aims to examine survival outcomes in elderly patients with inoperable stage I NSCLC treated with SBRT. METHODS A total of 31 patients with single lesions treated with fractionated SBRT from 2008 to 2011 were...

Stereotactic Body Therapy Radiation for the Treatment of Early Stage Non Small Cell Lung Cancer AUTHOR:

Stereotactic Body Radiation Therapy for the Treatment of Early Stage Non Small Cell Lung Cancer

The California Technology Assessment Forum was requested to review the scientific evidence for the use of Stereotactic Body Radiation Therapy (SBRT) for the treatment of early stage non small cell lung cancer (NSCLC) in medically inoperable patients. Given that the major treatment goal for non small cell lung cancer is to obtain local control, is SBRT a viable therapeutic option for patients wh...

Survey of Stereotactic Body Radiation Oncology for Early Staged Non-Small Cell Lung Cancer in China

Purpose: To evaluate the current status of stereotactic body radiotherapy (SBRT) for early staged non-small cell lung cancer (NSCLC) at main cancer hospitals in China. Methods and Materials: The questionnaire was sent by mail and email to 21 hospitals, which include the patient enrollment, treatment technique, dose and fractionation, quality control, disease control and side effects. Results: N...

Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy

The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and nati...